Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials
AbuMweis S, Jew S, Tayyem R, Agraib L
Journal of human nutrition and dietetics : the official journal of the British Dietetic Association · 82 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Hashemite University
Según 1 financiador declarado.
Publicación
- Publicado
- 2017-07-04 · J Hum Nutr Diet · vol. 31 · número 1 · págs. 67–84
- Editorial
- Wiley
- Citado
- 124 citas · más que el 98% de estudios similares · 6.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 193 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Natural Products and Biological Research · Food Chemistry and Fat Analysis
- Palabras clave
- Medicine, Docosahexaenoic acid, Eicosapentaenoic acid, Internal medicine, Jadad scale, Blood pressure, Meta-analysis, Placebo, Triglyceride, Confidence interval, Cochrane Library, Lipid profile, Blood lipids, Gastroenterology, Cholesterol, Endocrinology, Fatty acid, Polyunsaturated fatty acid, Biochemistry, Pathology
- MeSH
- humans, cardiovascular diseases, docosahexaenoic acids, eicosapentaenoic acid, triglycerides, c-reactive protein, blood pressure, heart rate, dietary supplements, adult, aged, middle aged, female, male, hemodynamics, young adult
4 autores
- Suhad Sameer AbuMweis🇯🇴 · autor de correspondenciaHashemite University
- Stephanie Jew🇨🇦University of Manitoba
- Reema Tayyem🇯🇴University of Jordan
- Lana M. Agraib🇯🇴Hashemite University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Over 200 clinical trials have examined the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplements on risk factors associated with cardiovascular disease. However, an updated analysis of the evidence is lacking. The aim of the present meta-analysis was to quantify the effect of supplements containing EPA and DHA on risk factors for cardiovascular disease.
Methods
An analysis was carried on 171 clinical trials with acceptable quality (Jadad score ≥3) that were identified from a comprehensive electronic search strategy of two databases (Pubmed and Cochrane Library). A random effect model was used to obtain an overall estimate on outcomes of interest. Heterogeneity between trial results was tested for using a standard chi-squared test.
Results
Compared with control, EPA and DHA supplements produced significant reductions of triglycerides of 0.368 mmol L-1 [95% confidence interval (CI) = -0.427 to -0.309], systolic blood pressure of 2.195 mmHg (95% CI = -3.172 to -1.217), diastolic blood pressure of 1.08 mmHg (95% CI = -1.716 to -0.444), heart rate of 1.37 bpm (95% CI = -2.41 to -0.325) and C-reactive protein of 0.343 mg L-1 (95% CI = -0.454 to -0.232). This analysis indicates an increase in both low-density lipoprotein cholesterol (mean difference = 0.150 mmol L-1 ; 95% CI = 0.058-0.243) and high-density lipoprotein cholesterol (mean difference = 0.039 mmol L-1 ; 95% CI = 0.024-0.054). The triglyceride-lowering effect was dose-dependent.
Conclusions
The lipid-lowering, hypotensive, anti-arrhythmic and anti-inflammatory actions of EPA and DHA supplements were confirmed in this analysis of randomised placebo-control blinded clinical trials.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.